John Parkinson

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Investigators found a couple of different factors for this phenomenon.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

Investigators looked to see if this population might be candidates for this form of HIV prevention.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

This decision was based from the analysis of the company’s phase 2 BLAZE-4 trial.

In this latest episode of Contagion Community, we interview Dr. Jacinda Abdul-Mutakabbir about vaccine equality vs vaccine equity as well as her experience on a COVID-19 vaccine drive to increase vaccinations in communities of color.

Their investigational vaccine, NVX-CoV2373, demonstrated 82% efficacy against the Delta variant in participants 12-17 years old.

A study looked at COVID-19 vaccination rates and new COVID-19 infections across US counties during the Delta surge last summer. Many of the highly infected counties were considered rural, highlighting some of the vaccination challenges surrounding these areas.

A process known as thin film freezing can convert existing therapies into powder that offers another delivery solution and may help alleviate storage challenges in developing countries.

The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted 13-0 in favor of the vaccine for adults.

A sub-analysis of phase 2 data compared the immunogenicity of their VLA15 vaccine in adults after administration of 2 or 3 primary series doses with the latter demonstrating a stronger response.

The company’s Spikvax vaccine was approved based on its submission that included efficacy and safety data approximately 6 months after second dose.

Company announced it had administered its first shot to a participant for its extension of an earlier phase 2 study.

The companies said the vaccines will be examined in adults 18-55 years old.

More than 1.2 million people were estimated to have died in 2019 as a direct result, and that antimicrobial-resistant infections played a role in millions more.

In utilizing a modeling study, investigators estimated reductions in HIV incidence rates as well as PrEP usage rates and viral suppression across US cities over 10 years.

A predictive tool, POC Advisor, has been developed to support faster diagnosis and intervention of this dangerous condition.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

The award given to the research institute by the state of Pennsylvania looks to delve deep in understanding vulnerable populations and taking some lessons away in addressing future potential pandemics.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

A pregnant woman is reported to be the country’s first person to be infected simultaneously with COVID-19 and influenza.

The country says one city hospital’s data shows a decrease in severity and mortality during this latest variant's outbreak.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.